Glycyrrhetinic acid as a hepatocyte targeting unit for an anticancer drug delivery system with enhanced cell type selectivity
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Singh, Hardev | - |
dc.contributor.author | Kim, Seo Jin | - |
dc.contributor.author | Kang, Dong Hoon | - |
dc.contributor.author | Kim, Hye-Ri | - |
dc.contributor.author | Sharma, Amit | - |
dc.contributor.author | Kim, Won Young | - |
dc.contributor.author | Kang, Chulhun | - |
dc.contributor.author | Kim, Jong Seung | - |
dc.date.accessioned | 2021-09-02T03:33:47Z | - |
dc.date.available | 2021-09-02T03:33:47Z | - |
dc.date.created | 2021-06-19 | - |
dc.date.issued | 2018-11-11 | - |
dc.identifier.issn | 1359-7345 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/71858 | - |
dc.description.abstract | Herein, we report the potential of glycyrrhetinic acid (GA) as an active targeting ligand for hepatocellular carcinoma (HCC) for the development of diagnosis/therapy using small-molecule based approaches. Our preliminary results demonstrated that GA-conjugation to diagnostic/therapeutic counterparts significantly enhanced their HCC targeting ability and excellent therapeutic efficacy. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | ROYAL SOC CHEMISTRY | - |
dc.subject | HEPATOCELLULAR-CARCINOMA | - |
dc.subject | IN-VIVO | - |
dc.subject | CANCER-THERAPY | - |
dc.subject | LIVER-CANCER | - |
dc.subject | CHEMOTHERAPY | - |
dc.subject | PRODRUG | - |
dc.subject | AGENTS | - |
dc.subject | THERANOSTICS | - |
dc.subject | DOXORUBICIN | - |
dc.subject | ACTIVATION | - |
dc.title | Glycyrrhetinic acid as a hepatocyte targeting unit for an anticancer drug delivery system with enhanced cell type selectivity | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Kim, Jong Seung | - |
dc.identifier.doi | 10.1039/c8cc05175e | - |
dc.identifier.scopusid | 2-s2.0-85055622506 | - |
dc.identifier.wosid | 000448823200015 | - |
dc.identifier.bibliographicCitation | CHEMICAL COMMUNICATIONS, v.54, no.87, pp.12353 - 12356 | - |
dc.relation.isPartOf | CHEMICAL COMMUNICATIONS | - |
dc.citation.title | CHEMICAL COMMUNICATIONS | - |
dc.citation.volume | 54 | - |
dc.citation.number | 87 | - |
dc.citation.startPage | 12353 | - |
dc.citation.endPage | 12356 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Chemistry | - |
dc.relation.journalWebOfScienceCategory | Chemistry, Multidisciplinary | - |
dc.subject.keywordPlus | HEPATOCELLULAR-CARCINOMA | - |
dc.subject.keywordPlus | IN-VIVO | - |
dc.subject.keywordPlus | CANCER-THERAPY | - |
dc.subject.keywordPlus | LIVER-CANCER | - |
dc.subject.keywordPlus | CHEMOTHERAPY | - |
dc.subject.keywordPlus | PRODRUG | - |
dc.subject.keywordPlus | AGENTS | - |
dc.subject.keywordPlus | THERANOSTICS | - |
dc.subject.keywordPlus | DOXORUBICIN | - |
dc.subject.keywordPlus | ACTIVATION | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.